DUBLIN--(BUSINESS WIRE)--Aug 28, 2018--The “Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Metastatic Renal Cell Carcinoma (mRCC) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018′ report provides comprehensive insights about marketed and Phase III products for Metastatic Renal Cell Carcinoma (mRCC) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Coverage of API manufacturers for Metastatic Renal Cell Carcinoma (mRCC) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.
This report provides a comprehensive understanding of the emerging Phase III therapies for Metastatic Renal Cell Carcinoma (mRCC) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
Key Topics Covered:
1. Report Introduction
2. Metastatic Renal Cell Carcinoma (mRCC): Overview
3. Comparative Analysis of Marketed and Emerging Products
4. Marketed Therapies
5. Emerging Therapies (Phase III)
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bzkftn/metastatic_renal?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180828005822/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Kidney Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/28/2018 04:27 PM/DISC: 08/28/2018 04:27 PM